Fertility preservation in breast cancer patients

Future Oncology

Volumn 10, Issue 10, 2014, Pages 1767-1777

  Hachem, Hady El ^a,b   Atallah, David ^a,b   Grynberg, Michael ^c,d  

^a SAINT JOSEPH UNIVERSITY   (Lebanon)

^b SAINT JOSEPH UNIVERSITY   (Lebanon)

^c HÔPITAL JEAN VERDIER   (France)

^d UNIVERSITÉ PARIS 13   (France)

Author keywords

breast cancer; embryo oocyte cryopreservation; fertility preservation; in vitro maturation

Indexed keywords

BRCA1 PROTEIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLLITROPIN; GONADORELIN AGONIST; LETROZOLE; METHOTREXATE; TAMOXIFEN; BIOLOGICAL MARKER;

BREAST CANCER; CANCER PATIENT; CANCER THERAPY; CLINICAL PROTOCOL; CRYOPRESERVATION; FEMALE; FERTILITY PRESERVATION; GENE MUTATION; HUMAN; IN VITRO STUDY; META ANALYSIS (TOPIC); OOCYTE CRYOPRESERVATION; OOCYTE MATURATION; OVARIAN TISSUE CRYOPRESERVATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCTION; REVIEW; BREAST NEOPLASMS; COMPLICATION; GENETICS; MUTATION; PATHOPHYSIOLOGY; PRIMARY OVARIAN INSUFFICIENCY; PROCEDURES; TUMOR SUPPRESSOR GENE;

BIOLOGICAL MARKERS; BREAST NEOPLASMS; FEMALE; FERTILITY PRESERVATION; GENES, BRCA1; GENES, BRCA2; HUMANS; MUTATION; PRIMARY OVARIAN INSUFFICIENCY;

EID: 84907919937     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.55     Document Type: Review

References (86)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics. CA Cancer J. Clin. 64(1), 9-29 (2014).
2. DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics. CA Cancer J. Clin. 64(1), 52-62 (2014).
3. Lee SJ, Schover LR, Partridge AH et al. American society of clinical oncology recommendations on fertility preservation in cancer patients. J. Clin. Oncol. 24(18), 2917-2931 (2006).
4. Perz J, Ussher J, Gilbert E. Loss, uncertainty, or acceptance: Subjective experience of changes to fertility after breast cancer. Eur. J. Cancer Care (Engl.) 23(4), 514-522 (2014).
5. Partridge AH, Gelber S, Peppercorn J et al. Web-based survey of fertility issues in young women with breast cancer. J. Clin. Oncol. 22(20), 4174-4183 (2004).
6. Loren AW, Mangu PB, Beck LN et al.; American Society of Clinical Oncology. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J. Clin. Oncol. 31(19), 2500-2510 (2013).
7. ISFP Practice Committee, Kim SS, Donnez J, Barri P et al. Recommendations for fertility preservation in patients with lymphoma, leukemia, and breast cancer. J. Assist. Reprod. Genet. 29(6), 465-468 (2012).
8. Ben-Aharon I, Shalgi R. What lies behind chemotherapy-induced ovarian toxicity?. Reproduction 144(2), 153-163 (2012).
9. Meirow D, Biederman H, Anderson RA, Wallace WH. Toxicity of chemotherapy and radiation on female reproduction. Clin. Obst. Gynecol. 53(4), 727-739 (2010).
10. Sonmezer M, Oktay K. Fertility preservation in female patients. Hum. Reprod. Update 10(3), 251-266 (2004).
11. Swain SM, Land SR, Ritter MW et al. Amenorrhea in premenopausal women on the doxorubicin-And-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial. Breast Cancer Res. Treat. 113(2), 315-320 (2009).
12. Mazonakis M, Varveris H, Damilakis J, Theoharopoulos N, Gourtsoyiannis N. Radiation dose to conceptus resulting from tangential breast irradiation. Int. J. Radiat. Oncol. Biol. Phys. 55(2), 386-391 (2003).
13. Braems G, Denys H, DeWever O et al. Use of tamoxifen before and during pregnancy. Oncologist 16(11), 47-151 (2006).
14. Davies C, Pan H, Godwin J et al. Long-Term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381(9869), 805-816 (2013).
15. Broekmans FJ, Soules MR, Fauser BC. Ovarian aging: Mechanisms and clinical consequences. Endocr. Rev. 30(5), 465-493 (2009).
16. Letourneau JM, Ebbel EE, Katz PP et al. Acute ovarian failure underestimates age-specific reproductive impairment for young women undergoing chemotherapy for cancer. Cancer 118(7), 1933-1939 (2012).
17. Partridge A, Gelber S, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Winer E. Age of menopause among women who remain premenopausal following treatment for early breast cancer: Long-Term results from International Breast Cancer Study Group Trials V and VI. Eur. J. Cancer 43(11), 1646-1653 (2007).
18. Nelson SM. Biomarkers of ovarian response: Current and future applications. Fertil. Steril. 99(4), 963-969 (2013).
19. Lutchman Singh K, Muttukrishna S, Stein RC et al. Predictors of ovarian reserve in young women with breast cancer. Br. J. Cancer 96(12), 1808-1816 (2007).
20. Anders C, Marcom PK, Peterson B et al. A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer. Cancer Invest. 26(3), 286-295 (2008).
21. Yu B, Douglas N, Ferin MJ et al. Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy. Cancer 116(9), 2099-2105 (2010).
22. Partridge AH, Ruddy KJ, Gelber S et al. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertil. Steril. 94(2), 638-644 (2010).
23. Anderson RA, Cameron DA. Pretreatment serum anti-Müllerian hormone predicts long-Term ovarian function and bone mass after chemotherapy for early breast cancer. J. Clin. Endocrinol. Metab. 96(5), 1336-1343 (2011).
24. Dillon KE, Sammel MD, Prewitt M et al. Pretreatment antimüllerian hormone levels determine rate of posttherapy ovarian reserve recovery: Acute changes in ovarian reserve during and after chemotherapy. Fertil. Steril. 99(2), 477-483 (2013).
25. Weghofer A, Dietrich W, Barad DH, Gleicher N. Live birth chances in women with extremely low-serum anti-Mullerian hormone levels. Hum. Reprod. 26(7), 1905-1909 (2011).
26. Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy?. The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries. Oncologist 12(9), 1044-1054 (2007).
27. Oktay K, Sönmezer M, Oktem O, Fox K, Emons G, Bang H. Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury. Oncologist 12(9), 1055-1066 (2007).
28. Kim SS, Lee JR, Jee BC et al. Use of hormonal protection for chemotherapy-induced gonadotoxicity. Clin. Obstet. Gynecol. 53(4), 740-752 (2010).
29. Yang B, Shi W, Yang J et al. Concurrent treatment with gonadotropin-releasing hormone agonists for chemotherapy-induced ovarian damage in premenopausal women with breast cancer: A meta-Analysis of randomized controlled trials. Breast 22(2), 150-157 (2013).
30. Herrero L, Martínez M, Garcia-Velasco JA. Current status of human oocyte and embryo cryopreservation. Curr. Opin. Obstet. Gynecol. 23(4), 245-250 (2011).
31. Edgar DH, Gook DA. A critical appraisal of cryopreservation (slow cooling versus vitrification) of human oocytes and embryos. Hum. Reprod. Update 18(5), 536-554, (2012).
32. First baby born of frozen embryo (1984). www.nytimes.com/1984/04/11/us/ first-baby-born-of-frozen-embryo.html
33. Practice Committees of American Society for Reproductive Medicine; Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: A guideline. Fertil. Steril. 99(1), 37-43 (2013).
34. Cobo A, Diaz C. Clinical application of oocyte vitrification: A systematic review and meta-Analysis of randomized controlled trials. Fertil. Steril. 96(2), 277-285 (2011).
35. Smith GD, Serafini PC, Fioravanti J et al. Prospective randomized comparison of human oocyte cryopreservation with slow-rate freezing or vitrification. Fertil. Steril. 94(6), 2088-2095 (2010).
36. Rienzi L, Romano S, Albricci L et al. Embryo development of fresh 'versus' vitrified metaphase II oocytes after ICSI: A prospective randomized sibling-oocyte study. Hum. Reprod. 25(1), 66-73 (2010).
37. Noyes N, Porcu E, Borini A. Over 900 oocyte cryopreservation babies born with no apparent increase in congenital anomalies. Reprod. Biomed. Online 18(6), 769-776 (2009).
38. Sánchez-Serrano M, Crespo J, Mirabet V et al. Twins born after transplantation of ovarian cortical tissue and oocyte vitrification. Fertil. Steril. 93(1), 268. e11-3 (2010).
39. Cahill DJ, Wardle PG, Harlow CR, Hunt LP, Hull MG. Expected contribution to serum oestradiol from individual ovarian follicles in unstimulated cycles. Hum. Reprod. 15(9), 1909-1912 (2000).
40. Gupta PB, Kuperwasser C. Contributions of estrogen to ER-negative breast tumor growth. J. Steroid. Biochem. Mol. Biol. 102(1-5), 71-78 (2006).
41. Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z. Fertility preservation in breast cancer patients: A prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J. Clin. Oncol. 23(19), 4347-4353 (2005).
42. Oktay K, Türkçüoglu I, Rodriguez-Wallberg KA. GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation. Reprod. Biomed. Online 20(6), 783-788 (2010).
43. Oktay K, Hourvitz A, Sahin G et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J. Clin. Endocrinol. Metab. 91(10), 3885-3890 (2006).
44. Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: A prospective controlled study. J. Clin. Oncol. 26(16), 2630-2635 (2008).
45. Tulandi T, Martin J, Al-Fadhli R et al. Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. Fertil. Steril. 85(6), 1761-1765 (2006).
46. Friedler S, Koc O, Gidoni Y, Raziel A, Ron-El R. Ovarian response to stimulation for fertility preservation in women with malignant disease: A systematic review and meta-Analysis. Fertil. Steril. 97(1), 125-133 (2012).
47. Lee S, Oktay K. Does higher starting dose of FSH stimulation with letrozole improve fertility preservation outcomes in women with breast cancer?. Fertil. Steril. 98(4), 961-964 (2012).
48. von Wolff M, Thaler CJ, Frambach T et al. Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase. Fertil. Steril. 92(4), 1360-1365 (2009).
49. Sönmezer M, Türkçüoʇlu I, Coşkun U, Oktay K. Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles. Fertil. Steril. 95(6), 2125.e9-1 (2011).
50. Baerwald AR, Adams GP, Pierson RA. Ovarian antral folliculogenesis during the human menstrual cycle: A review. Hum. Reprod. Update 18(1), 73-91 (2012).
51. Cakmak H, Katz A, Cedars MI, Rosen MP. Effective method for emergency fertility preservation: Random-start controlled ovarian stimulation. Fertil. Steril. 100(6),1673-1680 (2013).
52. Trounson A, Wood C, Kausche A. In vitro maturation and the fertilization and developmental competence of oocytes recovered from untreated polycystic ovarian patients. Fertil. Steril. 62(2), 353-362 (1994).
53. Chian R-C, Uzelac PS, Nargund G. In vitro maturation of human immature oocytes for fertility preservation. Fertil. Steril. 99(5), 1173-1181 (2013).
54. Child TJ, Abdul-Jalil AK, Gulekli B, Tan SL. In vitro maturation and fertilization of oocytes from unstimulated normal ovaries, polycystic ovaries, and women with polycystic ovary syndrome. Fertil. Steril. 76(5), 936-942 (2001).
55. Chian RC, Buckett WM, Too LL, Tan SL. Pregnancies resulting from in vitro matured oocytes retrieved from patients with polycystic ovary syndrome after priming with human chorionic gonadotropin. Fertil. Steril. 72(4), 639-642 (1999).
56. Gremeau A-S, Andreadis N, Fatum M et al. In vitro maturation or in vitro fertilization for women with polycystic ovaries?. a case-control study of 194 treatment cycles. Fertil Steril. 98(2), 355-360 (2012).
57. Fadini R, Dal Canto MB, Mignini Renzini M et al. Effect of different gonadotrophin priming on IVM of oocytes from women with normal ovaries: A prospective randomized study. Reprod. Biomed. Online 19(3), 343-351 (2009).
58. Fadini R, Mignini Renzini M, Dal Canto M et al. Oocyte in vitro maturation in normo-ovulatory women. Fertil. Steril. 99(5), 1162-1169 (2013).
59. de Vos M, Ortega-Hrepich C, Albuz FK, et al. Clinical outcome of nonhCG-primed oocyte in vitro maturation treatment in patients with polycystic ovaries and polycystic ovary syndrome. Fertil. Steril. 96(4), 860-864 (2011).
60. Grynberg M, El Hachem H, de Bantel A, Benard J, le Parco S, Fanchin R. In vitro maturation of oocytes: Uncommon indications. Fertil. Steril. 99(5), 1182-1188 (2013).
61. Maman E, Meirow D, Brengauz M, Raanani H, Dor J, Hourvitz A. Luteal phase oocytes retrieval and in vitro maturation is an optional procedure for urgent fertility preservation. Fertil Steril. 95(1), 64-67 (2011).
62. Child, TJ, Sylvestre C, Pirwany I, Tan SL. Basal serum levels of FSH and estradiol in ovulatory and anovulatory women undergoing treatment by in vitro maturation of immature oocytes. Hum. Reprod. 17(8), 1997-2002 (2002).
63. Berwanger AL, Finet A, El Hachem H, le Parco S, Hesters L, Grynberg M. New trends in female fertility preservation: In vitro maturation of oocytes. Future Oncol. 8(12), 1567-1573 (2012).
64. Shalom-Paz E, Almog B, Shehata F et al. Fertility preservation for breast-cancer patients using IVM followed by oocyte or embryo vitrification. Reprod. Biomed. Online 21(4), 566-571 (2010).
65. Buckett WM, Chian RC, Dean NL, Sylvestre C, Holzer HE, Tan SL. Pregnancy loss in pregnancies conceived after in vitro oocyte maturation, conventional in vitro fertilization, and intracytoplasmic sperm injection. Fertil. Steril. 90(3), 546-550 (2008).
66. Söderström-Anttila V, Salokorpi T, Pihlaja M, Serenius-Sirve S, Suikkari AM. Obstetric and perinatal outcome and preliminary results of development of children born after in vitro maturation of oocytes. Hum. Reprod. 21(6), 1508-1513 (2006).
67. Shu-Chi M, Jiann-Loung H, Yu-Hung L, Tseng-Chen S, Ming-I L, Tsu-Fuh Y. Growth and development of children conceived by in-vitro maturation of human oocytes. Early Hum. Dev. 82(10), 677-682 (2006).
68. Grynberg M, Poulain M, Sebag-Peyrelevade S, le Parco S, Fanchin R, Frydman N. Ovarian tissue and follicle transplantation as an option for fertility preservation. Fertil. Steril. 97(6), 1260-1268 (2012).
69. Donnez J, Dolmans MM, Pellicer A et al. Restoration of ovarian activity and pregnancy after transplantation of cryopreserved ovarian tissue: A review of 60 cases of reimplantation. Fertil. Steril. 99(6), 1503-1513 (2013).
70. Stern CJ, Gook D, Hale LG et al. First reported clinical pregnancy following heterotopic grafting of cryopreserved ovarian tissue in a woman after a bilateral oophorectomy. Hum. Reprod. 28(11), 2996-2999 (2013).
71. Huang JYJ, Buckett WM, Gilbert L, Tan SL, Chian RC. Retrieval of immature oocytes followed by in vitro maturation and vitrification: A case report on a new strategy of fertility preservation in women with borderline ovarian malignancy. Gynecol. Oncol.105(2), 542-544 (2007).
72. Fasano G, Moffa F, Dechène J, Englert Y, Demeestere I. Vitrification of in vitro matured oocytes collected from antral follicles at the time of ovarian tissue cryopreservation. Reprod. Biol. Endocrinol. 23(9), 150 (2011).
73. Dolmans M-M, Jadoul P, Gilliaux S et al. A review of 15 years of ovarian tissue bank activities. J. Assist. Reprod. Genet. 30(3), 305-314 (2013).
74. Dolmans M-M, Marinescu C, Saussoy P et al. Reimplantation of cryopreserved ovarian tissue from patients with acute lymphoblastic leukemia is potentially unsafe. Blood 116(16), 2908-2914 (2010).
75. Sánchez-Serrano M, Novella-Maestre E, Roselló-Sastre E, Camarasa N, Teruel J, Pellicer A. Malignant cells are not found in ovarian cortex from breast cancer patients undergoing ovarian cortex cryopreservation. Hum. Reprod. 24(9), 2238-2243 (2009).
76. Rosendahl M, Timmermans Wielenga V, Nedergaard L et al. Cryopreservation of ovarian tissue for fertility preservation: No evidence of malignant cell contamination in ovarian tissue from patients with breast cancer. Fertil. Steril. 95(6), 2158-2161 (2011).
77. Chung K, Donnez J, Ginsburg E, Meirow D. Emergency IVF versus ovarian tissue cryopreservation: Decision making in fertility preservation for female cancer patients. Fertil. Steril. 99(6), 1534-1542 (2013).
78. Rzepka-Górska I, Tarnowski B, Chudecka-Glaz A, Górski B, Zielinska D, Toloczko-Grabarek A. Premature menopause in patients with BRCA1 gene mutation. Breast Cancer Res. Treat. 100(1), 59-63 (2006).
79. Lin WT, Beattie M, Chen LM et al. Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non-clinic-based sample of women in northern California. Cancer 119(9), 1652-1659 (2013).
80. Oktay K, Kim JY, Barad D, Babayev SN. Association of BRCA1 mutations with occult primary ovarian insufficiency: A possible explanation for the link between infertility and breast/ovarian cancer risks. J. Clin. Oncol. 28(2), 240-244 (2010).
81. Gerhardus, A., Schleberger, H., Schlegelberger, B., Gadzicki, D. Diagnostic accuracy of methods for the detection of BRCA1 and BRCA2 mutations: A systematic review. Eur. J. Hum. Genet. 15(6), 619-627 (2007).
82. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302(5645), 643-646 (2003).
83. Sagi M, Weinberg N, Eilat A et al. Preimplantation genetic diagnosis for BRCA1/2-A novel clinical experience. Prenat. Diagn. 29(5), 508-513 (2009).
84. Goodwin PJ, Phillips KA, West DW et al. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: An International Prospective Breast Cancer Family Registry population-based cohort study. J. Clin. Oncol. 30(1), 19-26 (2012).
85. Menon U, Harper J, Sharma A et al. Views of BRCA gene mutation carriers on preimplantation genetic diagnosis as a reproductive option for hereditary breast and ovarian cancer. Hum. Reprod. 22(6), 1573-1577 (2007).
86. Donnelly LS, Watson M, Moynihan C et al. Reproductive decision-making in young female carriers of a BRCA mutation. Hum. Reprod. 28(4), 1006-1012 (2013).